艾多沙班获批信息: 1.另外一同获批的15mg,60mg规格。 2.本品原研日本第一三共制药,Edoxaban是一种口服的凝血因子Xa(factor Xa)抑制剂。2011年4月率先在日本上市,用于静脉血栓栓塞症(VTE)。2015年1月在美国获批用于降低非心脏瓣膜病引起的房颤患者卒...
A total of 130 patients receiving edoxaban 60mg (EDO) treatment were compared with the same number of VKA recipients. The mean follow-up was 16 (2.6) months. The cumulative incidence of thromboembolic events in the EDO and VKA groups was 1.5% (2 of 130) and 2.3% (3 of 130), ...
Across all age groups, the estimated median exposures were within the 0.5- to 1.5-fold of the median area under the plasma drug concentration-time curve (AUC) in adult subjects receiving corresponding doses (30mg q.d. for low dose and 60mg q.d. for high dose). In all age groups, ...